BCWM
SRPT icon

Bartlett & Co Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Bartlett & Co Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3
Closed -$224 – 1095
2021
Q1 		$224 Hold
3
– – ﹤0.01% 1088
2020
Q4 		$511 Buy
+3
New +$445 ﹤0.01% 1146

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bartlett & Co Wealth Management's SRPT Position: Q2 2021 in Review

Bartlett & Co Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 3 shares — an estimated $224 sold.

Bartlett & Co Wealth Management first reported a position in SRPT in Q4 2020 and held it in 2 quarters. The position peaked at $511 in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Bartlett & Co Wealth Management reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 3 Sarepta Therapeutics shares in Q2 2021, an estimated $224.
  • Bartlett & Co Wealth Management first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 2 quarters.
  • Bartlett & Co Wealth Management's Sarepta Therapeutics position peaked at $511 in Q4 2020.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2021, filed 14 Feb 2024.